MedTrace Logo

ABSORB Clinical Investigation, Cohort A (ABSORB A) Everolimus Eluting Coronary Stent System Clinical Investigation

NCT00300131 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2011-09-13

No results posted yet for this study

Summary

Prospective, open-labeled First in Man Clinical Investigation enrolling patients with visually estimated nominal vessel diameter of 3.0 mm receiving a single 3.0 x 12 mm or 3.0 x 18 mm BVS EECSS containing 98 microgramme per cm² of surface area.

Conditions

Interventions

DEVICE

Bioabsorbable Everolimus Eluting Coronary Stent

Bioabsorbable drug eluting stent implantation stent in the treatment of coronary artery disease

Sponsors & Collaborators

  • Abbott Medical Devices

    lead INDUSTRY

Principal Investigators

  • John Ormiston, MD · Auckland City Hospital

  • Patrick Serruys, MD · Erasmus University Thorax Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2011-07-31
Completion
2011-07-31

Countries

  • Denmark
  • Netherlands
  • New Zealand
  • Poland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00300131 on ClinicalTrials.gov